PMID- 30271490
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 9
IP  - 18
DP  - 2018
TI  - Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing 
      Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell 
      Carcinoma.
PG  - 3303-3310
LID - 10.7150/jca.25693 [doi]
AB  - Purpose: This study aimed to identify the survival benefit and safety of 
      alternative dosage schedules for sunitinib in metastatic renal cell carcinoma. 
      Materials and Methods: Clinicopathologic and survival data of patients treated 
      with sunitinib as first-line therapy were retrospectively reviewed. Patients were 
      classified into three groups: a standard dosing schedule (4/2 schedule), 
      alternative dosing schedule (2/1 schedule), and switched dosing schedule (4/2-2/1 
      schedule). Results: Ninety-nine patients were retrospectively included. 
      Seventy-five (75.8%) patients were initially administrated with a 4/2 schedule of 
      sunitinib, while 24 were started with the 2/1 schedule. During treatment, 45 
      (60.0%) patients with an initial 4/2 schedule switched to a 2/1 schedule (4/2-2/1 
      schedule) due to severe adverse events (AEs) or poor tolerance. Compared to that 
      with a 4/2 schedule, patients with a 2/1 schedule had a much lower incidence of 
      grade 3/4 AEs (69.6% vs. 40.6%, p=0.001). Overall, the 4/2-2/1 schedule was 
      associated with the best survival benefits. Among the 4/2, 2/1, and 4/2-2/1 
      schedule groups, the median PFS was 12.5, 11.0, and 25.0 months, respectively 
      (p=0.003), and the median OS was 21.0, 28.0, and 52.0 months, respectively 
      (p=0.03). Multivariate analysis identified the 4/2-2/1 schedule as an independent 
      factor predicting favorable PFS. Although without statistical significance, 
      4/2-2/1 schedule could decrease 55% risk of death. Furthermore, patients with 
      unfavorable IMDC risk seemed to have more opportunity to achieve better survival 
      from the 4/2-2/1 dosing schedule. Conclusion: Patients with a 4/2-2/1 schedule 
      could minimize treatment-related toxicities; more importantly, patients with 
      4/2-2/1 schedule could achieve a superior survival benefit.
FAU - Zhang, Xingming
AU  - Zhang X
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Sun, Guangxi
AU  - Sun G
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Zhao, Jinge
AU  - Zhao J
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Shu, Kunpeng
AU  - Shu K
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Zhao, Peng
AU  - Zhao P
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Liu, Jiandong
AU  - Liu J
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Yang, Yaojing
AU  - Yang Y
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Tang, Qidun
AU  - Tang Q
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Chen, Junru
AU  - Chen J
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Shen, Pengfei
AU  - Shen P
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Wang, Jia
AU  - Wang J
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
FAU - Zeng, Hao
AU  - Zeng H
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, China, 610041.
LA  - eng
PT  - Journal Article
DEP - 20180907
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC6160671
OTO - NOTNLM
OT  - clinical outcome, dosing schedule, metastatic renal cell carcinoma
OT  - safety profile
OT  - sunitinib
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2018/10/03 06:00
MHDA- 2018/10/03 06:01
PMCR- 2018/01/01
CRDT- 2018/10/02 06:00
PHST- 2018/02/23 00:00 [received]
PHST- 2018/06/16 00:00 [accepted]
PHST- 2018/10/02 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2018/10/03 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - jcav09p3303 [pii]
AID - 10.7150/jca.25693 [doi]
PST - epublish
SO  - J Cancer. 2018 Sep 7;9(18):3303-3310. doi: 10.7150/jca.25693. eCollection 2018.